Efficacy News and Research

RSS

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Blockade Medical’s Barricade Coil System receives CE Mark

Blockade Medical announced today that it has received CE Mark (Conformité Européenne) for its Barricade Coil System. The Barricade Coil System is designed to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

20 Jul 2012

Glanbia Nutritionals, ChromaDex to distribute pTeroPure in North America

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure, announced today a distribution agreement for pTeroPure with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company.

19 Jul 2012

Additional research required to assess effectiveness of herbal remedies for insomnia

Approximately 1 in 3 Americans suffers from chronic sleep deprivation and another 10-15% of the population has chronic insomnia. Sleep disorders can profoundly affect a person's whole life and have been linked to a range of diseases, including obesity, depression, anxiety, and inflammatory disorders.

19 Jul 2012

EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review

Pfizer Inc. today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.

19 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Duke receives Gates Foundation grant for HIV vaccine study

The Bill & Melinda Gates Foundation has awarded a new grant to Duke University Medical Center for work developing vaccines that can induce IgA antibodies for preventing HIV-1 infection. This award comes from the Gates' Collaboration for AIDS Vaccine Discovery (CAVD) program.

19 Jul 2012

Vaccination more reliable than observation for bovine herpesvirus

Vaccination halts the circulation of bovine herpesvirus type 1 in dairy herds and should been seen as the best way to eradicate the virus, despite it disappearing without intervention in some herds after long periods, report researchers in the Veterinary Record.

18 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Medica releases EasyCell solution for hematology laboratories

Medica Corporation, a provider of easy-to-use, low-cost blood testing analyzers, announced today the global release of its EasyCell assistant cell image analyzer for hematology laboratories.

From Medica Corporation 18 Jul 2012

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.

18 Jul 2012

Computerized mobilization eases chronic neck pain

Computerized mobilization of the cervical spine appears to be a viable treatment option for patients with chronic neck pain, a proof-of-concept trial shows.

17 Jul 2012

UIC develops new tool to guide decisions about safe and effective medication use

A new tool to guide decisions about safe and effective medication use has been developed at the University of Illinois at Chicago College of Pharmacy.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.

17 Jul 2012

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.

17 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012